EE03826B1 - Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode - Google Patents

Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode

Info

Publication number
EE03826B1
EE03826B1 EE9700253A EE9700253A EE03826B1 EE 03826 B1 EE03826 B1 EE 03826B1 EE 9700253 A EE9700253 A EE 9700253A EE 9700253 A EE9700253 A EE 9700253A EE 03826 B1 EE03826 B1 EE 03826B1
Authority
EE
Estonia
Prior art keywords
preparation
compound
combination
pharmaceutical composition
product containing
Prior art date
Application number
EE9700253A
Other languages
English (en)
Estonian (et)
Other versions
EE9700253A (et
Inventor
Joseph Kukla Michael
Adriaan Jan Janssen Paul
Emiel Lodewijk Moereels Henri
William Ludovici Donald
Heeres Jan
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE9700253A publication Critical patent/EE9700253A/xx
Publication of EE03826B1 publication Critical patent/EE03826B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
EE9700253A 1996-10-01 1997-09-26 Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode EE03826B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2726096P 1996-10-01 1996-10-01

Publications (2)

Publication Number Publication Date
EE9700253A EE9700253A (et) 1998-04-15
EE03826B1 true EE03826B1 (et) 2002-08-15

Family

ID=21836641

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700253A EE03826B1 (et) 1996-10-01 1997-09-26 Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode

Country Status (34)

Country Link
US (4) US6380194B1 (pl)
EP (1) EP0834507B1 (pl)
JP (1) JP4127882B2 (pl)
KR (1) KR100478846B1 (pl)
CN (1) CN1083438C (pl)
AP (1) AP914A (pl)
AR (1) AR008864A1 (pl)
AT (1) ATE267179T1 (pl)
AU (1) AU740809B2 (pl)
BR (1) BR9704937A (pl)
CA (1) CA2216486A1 (pl)
CZ (1) CZ297333B6 (pl)
DE (1) DE69729153T2 (pl)
DK (1) DK0834507T3 (pl)
EE (1) EE03826B1 (pl)
ES (1) ES2221679T3 (pl)
HK (1) HK1009676A1 (pl)
HR (1) HRP970526B1 (pl)
HU (1) HU225270B1 (pl)
ID (1) ID19599A (pl)
IL (1) IL121849A (pl)
MY (1) MY123803A (pl)
NO (1) NO311614B1 (pl)
NZ (1) NZ328854A (pl)
OA (1) OA10620A (pl)
PL (1) PL190155B1 (pl)
PT (1) PT834507E (pl)
RU (1) RU2186774C2 (pl)
SG (1) SG53075A1 (pl)
SI (1) SI0834507T1 (pl)
SK (1) SK285241B6 (pl)
TR (1) TR199701070A2 (pl)
TW (1) TW411335B (pl)
ZA (1) ZA978766B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
US6638932B1 (en) * 1998-11-10 2003-10-28 Janssen Pharmaceutica N.V. 2,4-disubstituted triazine derivatives
OA11674A (en) * 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
EA005423B1 (ru) * 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
JP2003519143A (ja) * 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
EP1282606B1 (en) 2000-05-08 2015-04-22 Janssen Pharmaceutica NV Hiv replication inhibiting pyrimidines and triazines
ATE458724T1 (de) * 2001-06-26 2010-03-15 Bristol Myers Squibb Co N-heterocyclische inhibitoren der expression von tnf-alpha
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
EA007578B1 (ru) 2001-11-01 2006-12-29 Янссен Фармацевтика Н.В. Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета
CA2463822A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
WO2003097806A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7476741B2 (en) * 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AU2004213173B2 (en) * 2003-02-07 2010-07-29 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazines
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
US7923554B2 (en) 2004-08-10 2011-04-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
CA2578995A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use
KR20070057798A (ko) 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
WO2006035069A1 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-substituted pyrimidines
AU2005288864B2 (en) 2004-09-30 2012-08-23 Janssen Sciences Ireland Uc HIV inhibiting 5-heterocyclyl pyrimidines
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
CA2612227C (en) 2005-06-14 2014-04-22 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
ES2465666T3 (es) 2006-03-30 2014-06-06 Janssen R&D Ireland Pirimidinas 5-amido-sustituidas inhibidoras del HIV
EP2114901B1 (en) 2006-12-29 2014-04-09 Janssen R&D Ireland Hiv inhibiting 6-substituted pyrimidines
EP2114902B1 (en) 2006-12-29 2014-09-17 Janssen R&D Ireland Hiv inhibiting 5,6-substituted pyrimidines
JP5450381B2 (ja) * 2007-04-30 2014-03-26 プロメティック・バイオサイエンスィズ・インコーポレーテッド 化合物、そのような化合物を含有する組成物、及びそのような化合物を用いるがん及び自己免疫疾患の治療法
KR101579999B1 (ko) 2008-04-21 2015-12-23 타이젠 바이오테크놀러지 컴퍼니 리미티드 헤테로사이클릭 화합물
US9023834B2 (en) 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
US9058223B2 (en) * 2011-04-22 2015-06-16 Microsoft Technology Licensing Llc Parallel entropy encoding on GPU
WO2014064094A1 (en) * 2012-10-24 2014-05-01 Basf Se Herbicidal azines
US10941122B2 (en) * 2014-04-11 2021-03-09 Basf Se Diaminotriazine derivatives as herbicides
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
CN105837525B (zh) * 2016-03-25 2019-05-28 浙江工业大学 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE226474C (pl)
US2309663A (en) * 1943-01-26 Process fok preparing substituted
US2817814A (en) 1953-08-13 1957-12-24 Gen Electric Corona detection probe
GB771327A (en) 1953-10-26 1957-03-27 Monsanto Chemicals Production of heat hardenable melamine-formaldehyde condensation products
US2817614A (en) * 1953-10-26 1957-12-24 Monsanto Chemicals Internally plasticized melamine resins and laminates made therewith
JPS4927592B1 (pl) * 1970-05-13 1974-07-18
GB1390235A (en) 1971-08-07 1975-04-09 Kakenyaku Kako Kk 2-amino-4,6substituted-s triazines and methods for their preparation
DE3724379A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Verfahren zur herstellung feinteiliger magnetischer hexaferritpigmente
AU2599992A (en) * 1991-11-12 1993-06-15 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater

Also Published As

Publication number Publication date
US7449575B2 (en) 2008-11-11
MY123803A (en) 2006-06-30
KR100478846B1 (ko) 2006-06-13
PT834507E (pt) 2004-10-29
HUP9701596A2 (hu) 1999-06-28
HU9701596D0 (en) 1997-11-28
HRP970526A2 (en) 1998-10-31
DK0834507T3 (da) 2004-09-06
AR008864A1 (es) 2000-02-23
CN1083438C (zh) 2002-04-24
ES2221679T3 (es) 2005-01-01
TR199701070A2 (xx) 1998-04-21
ID19599A (id) 1998-07-23
HU225270B1 (en) 2006-08-28
US6858609B2 (en) 2005-02-22
HUP9701596A3 (en) 2000-04-28
PL322369A1 (en) 1998-04-14
AP914A (en) 2000-12-18
AU3926697A (en) 1998-04-09
ZA978766B (en) 1999-03-30
RU2186774C2 (ru) 2002-08-10
US6962916B2 (en) 2005-11-08
EP0834507A1 (en) 1998-04-08
EP0834507B1 (en) 2004-05-19
NZ328854A (en) 2000-10-27
KR19980032428A (ko) 1998-07-25
SK285241B6 (sk) 2006-09-07
HK1009676A1 (en) 1999-06-04
AU740809B2 (en) 2001-11-15
MX9707511A (es) 1998-06-30
SG53075A1 (en) 1998-09-28
US6380194B1 (en) 2002-04-30
EE9700253A (et) 1998-04-15
US20030199473A1 (en) 2003-10-23
IL121849A (en) 2001-08-26
BR9704937A (pt) 2000-06-06
NO974368D0 (no) 1997-09-22
ATE267179T1 (de) 2004-06-15
US20020147181A1 (en) 2002-10-10
IL121849A0 (en) 1998-02-22
SI0834507T1 (en) 2004-10-31
DE69729153T2 (de) 2005-01-27
SK131997A3 (en) 1999-06-11
CZ299397A3 (cs) 1998-11-11
OA10620A (en) 2002-09-03
JP4127882B2 (ja) 2008-07-30
DE69729153D1 (de) 2004-06-24
JPH10114759A (ja) 1998-05-06
NO311614B1 (no) 2001-12-17
PL190155B1 (pl) 2005-11-30
NO974368L (no) 1998-04-02
US20060189614A1 (en) 2006-08-24
AP9701109A0 (en) 1997-10-31
CZ297333B6 (cs) 2006-11-15
CA2216486A1 (en) 1998-04-01
CN1180698A (zh) 1998-05-06
TW411335B (en) 2000-11-11
HRP970526B1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
EE03826B1 (et) Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode
EE200100318A (et) Kinoliini derivaat, selle ühendi kasutamine ravimina, seda sisaldav farmatseutiline kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
SI1156049T1 (en) Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
FI964473A0 (fi) Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset (II)
EE05086B1 (et) Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
HUT71130A (en) Condensed indole derivatives of protein kinase c inhibitor activity, process for preparing them and pharmaceutical compositions containing them
ZA968945B (en) 1,3-Dihydro-indol-2-one derivatives process for their preparation and the pharmaceutical compositions containing them
SI0780390T1 (en) Crystalline modification of CDCH, process for its preparation and pharmaceutical compositions containing it
HUP9601033A3 (en) Benzofurane derivatives, process for their preparation, use of them as intermediate and pharmaceutical compositions containing the compounds
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
HUP9901326A3 (en) Benzopyran derivatives having leukotriene-antagonistic action, pharmaceutical compositions containing these compounds, process for the preparation and use of these compounds and compositions
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
CZ346595A3 (en) Substituted derivatives of 4-phenylthiazoles, process of their preparation and pharmaceutical compositions containing thereof
FI960316A0 (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
HUP9601680A3 (en) Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds
EE200200331A (et) Hargnenud ahelaga asendatud 3-amino-1-fenüül-1H-[1,2,4]triasooli aminoderivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200100253A (et) 2,4-diasendatud triasiiniderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
EE03773B1 (et) Kondenseeritud imidasoolderivaadid, nende kasutamine ravimina, neid sisaldav farmatseutiline kompositsioon, meetod selle valmistamiseks ning seda sisaldav kombineeritud preparaat
HUP9602324A3 (en) Piperidinyl-methyl-oxazolidinon derivatives, pharmaceutical compositions containing the same, process for the preparation of the compounds and use of them
HUP9601712A3 (en) Substituted benzothiazine derivatives, intermediates of them, process for their preparation and pharmaceutical compositions containing the same
HUP0000854A3 (en) 4-(6-fluoro-(1h)-indol-3-yl)-1,2,3,6-tetrahydropyridine derivatives, pharmaceutical compositions containing them and process for the preparation of both
HU901569D0 (en) Process for the preparation of triazine derivatives and pharmaceutical compositions containing such compounds
EE04155B1 (et) 2,4,4-triasendatud-1,3-dioksolaanid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon, kombinatsioon ja produkt
HUP0001441A3 (en) Process for the preparation of pharmaceutical compositions containing 4-aza-androst-1-ene derivatives
HUP0003463A3 (en) Piperidinylmethyloxazolidinone derivative, process for its preparation pharmaceutical compositions containing it and use thereof

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20070926